COVID-19 represents a chance for pharma to recruit the best of the next-generation, says PTC's Hege Sollie-Zetlmayer

hege_sollie_zetlmayer_large

Nobody can doubt that the pharmaceutical industry is home to some very smart and ambitious minds, but it is also true that sometimes the sector has missed out to other careers in attracting top talent.

But the COVID-19 pandemic’s impact on almost every aspect of society, and the role of pharma in returning the world to normal, could make the industry a first choice for many outstanding graduates that might previously have been looking elsewhere.

Image problem

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical